名稱 | bTMB-P1 (22.91) Reference Standard |
型號(hào) | CBP80001-10 |
報(bào)價(jià) | ![]() |
特點(diǎn) | bTMB-P1 (22.91) Reference Standard |
產(chǎn)品搜索
相關(guān)文章
- 【新品發(fā)布】血液系統(tǒng)惡性腫瘤標(biāo)準(zhǔn)品-27基因-38位點(diǎn)
- PD-1/L1 &4-1BB雙靶點(diǎn)細(xì)胞篩選模型
- PIK3CA診斷標(biāo)準(zhǔn)品
- FGFR2融合靶向藥物細(xì)胞篩選模型
- *針對(duì)肝癌的PD-1抗體獲FDA批準(zhǔn),國產(chǎn)PD-1抗體進(jìn)入三期
- 【產(chǎn)品推介】腫瘤融合基因檢測(cè)及靶向治療
- 科佰生物提前祝大家中秋快樂,闔家團(tuán)圓!
- ATCC細(xì)胞單純的固定液一般難以達(dá)到這些要求
- PIM-1激酶抑制劑細(xì)胞篩選模型
- CD200/CD200R篩選模型
聯(lián)系我們
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
基因檢測(cè)標(biāo)準(zhǔn)品 > 其他類別 > CBP80001-10bTMB-P1 (22.91) Reference Standard

- 詳細(xì)內(nèi)容
CBP80001-10 | |||||||||||||||||||||||||||||||||||||||||||||||
I. Background | |||||||||||||||||||||||||||||||||||||||||||||||
Tumor mutational burden (TMB) shows great promise as a biomarker for immuno-oncology (I-O) therapy response, but progress is hindered by the lack of a standardized TMB measurement by targeted NGS panels, and an absence of TMB reference materials.
| |||||||||||||||||||||||||||||||||||||||||||||||